Kyongbo Pharmaceutical Co Ltd (214390) — Cash Flow Quality Index
Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow Quality Index of 1.49x as of September 2025. Operating cash flow of ₩4.51 Billion exceeds net income of ₩3.03 Billion, indicating high earnings quality where cash backs reported profits. Explore 214390 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Kyongbo Pharmaceutical Co Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for Kyongbo Pharmaceutical Co Ltd across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 214390 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Kyongbo Pharmaceutical Co Ltd (2014–2024)
Year-by-year earnings quality comparison for Kyongbo Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see Kyongbo Pharmaceutical Co Ltd (214390) market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | ₩149.12 Million | ₩4.64 Billion | ▼ -98.0% |
| 2023 | 1.63x | ₩4.84 Billion | ₩2.97 Billion | ▼ -90.2% |
| 2022 | 16.59x | ₩10.13 Billion | ₩610.59 Million | ▲ +650.0% |
| 2020 | 2.21x | ₩20.80 Billion | ₩9.40 Billion | ▼ -50.6% |
| 2019 | 4.48x | ₩23.67 Billion | ₩5.29 Billion | ▲ +5260.6% |
| 2018 | -0.09x | ₩-1.14 Billion | ₩13.12 Billion | ▼ -106.0% |
| 2017 | 1.44x | ₩25.81 Billion | ₩17.96 Billion | ▼ -27.9% |
| 2016 | 1.99x | ₩25.33 Billion | ₩12.71 Billion | ▲ +1127.5% |
| 2015 | 0.16x | ₩4.24 Billion | ₩26.11 Billion | ▼ -91.3% |
| 2014 | 1.86x | ₩16.04 Billion | ₩8.64 Billion | — |